Penumbra Gross Margin 2014-2025 | PEN
Penumbra Gross Margin Historical Data | |||
---|---|---|---|
Date | TTM Revenue | TTM Gross Profit | Gross Margin |
2025-03-31 | $1.24B | $0.79B | 63.71% |
2024-12-31 | $1.20B | $0.76B | 63.18% |
2024-09-30 | $1.16B | $0.73B | 62.80% |
2024-06-30 | $1.13B | $0.71B | 62.52% |
2024-03-31 | $1.10B | $0.71B | 65.05% |
2023-12-31 | $1.06B | $0.68B | 64.56% |
2023-09-30 | $0.99B | $0.63B | 63.78% |
2023-06-30 | $0.94B | $0.59B | 63.07% |
2023-03-31 | $0.88B | $0.56B | 63.12% |
2022-12-31 | $0.85B | $0.53B | 63.05% |
2022-09-30 | $0.83B | $0.52B | 62.77% |
2022-06-30 | $0.81B | $0.51B | 62.78% |
2022-03-31 | $0.78B | $0.49B | 62.79% |
2021-12-31 | $0.75B | $0.48B | 63.59% |
2021-09-30 | $0.71B | $0.44B | 62.54% |
2021-06-30 | $0.67B | $0.42B | 61.85% |
2021-03-31 | $0.59B | $0.36B | 60.98% |
2020-12-31 | $0.56B | $0.34B | 60.36% |
2020-09-30 | $0.54B | $0.34B | 63.57% |
2020-06-30 | $0.53B | $0.35B | 65.84% |
2020-03-31 | $0.56B | $0.38B | 67.63% |
2019-12-31 | $0.55B | $0.37B | 68.01% |
2019-09-30 | $0.52B | $0.35B | 67.50% |
2019-06-30 | $0.50B | $0.33B | 67.07% |
2019-03-31 | $0.47B | $0.31B | 65.82% |
2018-12-31 | $0.45B | $0.29B | 65.70% |
2018-09-30 | $0.42B | $0.28B | 66.03% |
2018-06-30 | $0.39B | $0.26B | 65.65% |
2018-03-31 | $0.36B | $0.24B | 65.11% |
2017-12-31 | $0.33B | $0.22B | 65.27% |
2017-09-30 | $0.31B | $0.20B | 64.63% |
2017-06-30 | $0.29B | $0.19B | 64.29% |
2017-03-31 | $0.28B | $0.18B | 64.39% |
2016-12-31 | $0.26B | $0.17B | 65.02% |
2016-09-30 | $0.24B | $0.16B | 65.57% |
2016-06-30 | $0.23B | $0.15B | 66.08% |
2016-03-31 | $0.20B | $0.14B | 66.67% |
2015-12-31 | $0.19B | $0.12B | 66.49% |
2015-06-30 | $0.11B | $0.08B | 66.37% |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | MED INSTRUMENTS | $11.301B | $1.195B |
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. |